China uses AI to treat lung cancer
As the use of artificial intelligence (AI) is on the rise within the healthcare industry, China is quickly embracing the technology to tackle lung cancer.
The country has one of the highest rates of lung cancer in the world, with an estimated 300mn smokers and hazardous air pollution, especially within the industrialised northern regions.
It has been predicted that by 2020 there will be an annual rate of 800,000 diagnoses and 700,000 deaths, according to Time Magazine.
There are also approximately 80,000 radiologists in the country, who examine around 1.4bn radiology scans per year.
AI ca be connected to scanners, which could improve the medical diagnosis procedure, through the processing of computed tomography scans and X-rays.
This technology can spot potentially dangerous lesions and nodules in patients.
The Shanghai Changzheng Hospital has been testing out this method, using technology created by Infervision.
“Our goal at Infervision is to build a stronger medical industry and help accelerate diagnoses which is so important for patient,” stated Chen Kuan, Infervision’s founder and CEO.
The Chinese startup is working with big technology companies, such as GE Healthcare, Cisco, and Nvidia, with the technology being tested in more than 20 tertiary grade A hospitals across the nation.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”